60 Degrees Pharmaceuticals (SXTP) announced the approval of an Investigational Review Board, IRB, sanctioned Phase II clinical study. The study will evaluate the efficacy and safety of the ARAKODA regimen over 90 days for treating patients with a presumptive diagnosis of chronic babesiosis. Participants will have experienced significant functional impairment for at least six months. Patient enrollment is expected to begin in Q3 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP: